Frazier Life Sciences — 2017 Investments
4 investments dated 2017 · listed companies and verified rows first · show all
BiotechAnn Arbor, US
Carol Gallagher(Director)Randall Whitcomb(Director)James Topper(Director)Julia C. Owens(Executive Officer, Director)William Harrington(Director)
Board seatJames N. Topper· per SEC Form D · $59.1M raise · filed Dec 2017
Seattle, US
Hendrik Struik(Executive Officer, Director, Promoter)George Willett(Executive Officer, Promoter)Nader Naini(Director, Promoter)Kenneth Hanover(Director, Promoter)Joe Whitters(Director, Promoter)Ben Magnano(Director, Promoter)
Board seatNader Naini· per SEC Form D · $32.3M raise · filed Jul 2017
BiotechWaltham, US
Michael Ross(Director)Oliver Rosen, M.D.(Executive Officer)Thomas Kelly(Executive Officer)John Martin(Director)Daniel F. Flynn, Ph.D.(Executive Officer)Liam Ratcliffe, M.D., Ph.D.(Director)
Krystal Biotech develops and commercializes redosable gene therapies to treat severe, rare, and life-threatening diseases with limited or no approved treatments.
BiotechMedical DevicesPittsburgh, US
Doug Norby(Director)Dino Rossi(Director)Suma M. Krishnan(Director)Krish S. Krishnan(Executive Officer, Director)
BoardDan Janney(Director)
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.